Premium
PHASED VARIANTS IMPROVE DLBCL MINIMAL RESIDUAL DISEASE DETECTION AT THE END OF THERAPY
Author(s) -
Kurtz D. M,
Chabon J. J,
Soo J,
Co Ting Keh L,
Alig S,
Schultz A,
Jin M. C,
Scherer F,
Craig A. F. M,
Liu C. L,
Dührsen U,
Hüttmann A,
Casasnovas R.O,
Westin J. R,
Roschewski M,
Wilson W. H,
Gaidano G,
Rossi D,
Diehn M,
Alizadeh A. A
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.25_2879
Subject(s) - minimal residual disease , duplex (building) , oncology , medicine , dna sequencing , dna , biology , genetics , leukemia